Protagenic Therapeutics Stock Today
Protagenic Therapeutics is selling for under 0.0034 as of the 23rd of March 2025; that is No Change since the beginning of the trading day. The stock's lowest day price was 0.0032. The performance scores are derived for the period starting the 23rd of December 2024 and ending today, the 23rd of March 2025. Click here to learn more.
Valuation
Check how we calculate scores
Protagenic Stock Highlights
| Business Concentration | Business Services, Biotechnology, Healthcare, Health Care, Biotechnology, Materials, Materials (View all Sectors) |
Protagenic Therapeutics (PTIXW) is traded on NASDAQ Exchange in USA. It is located in 149 Fifth Avenue, New York, NY, United States, 10010 and employs 1 people. Protagenic Therapeutics is listed under Business Services category by Fama And French industry classification. The company classifies itself under Biotechnology sector and is part of Health Care industry.
Protagenic Therapeutics has accumulated about 671.09 K in cash with (3.7 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.06, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Protagenic Therapeutics Probability Of Bankruptcy
Protagenic Therapeutics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Protagenic Therapeutics market risk premium is the additional return an investor will receive from holding Protagenic Therapeutics long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.0217 | |||
| Jensen Alpha | 0.4852 | |||
| Total Risk Alpha | 2.43 | |||
| Sortino Ratio | 0.0141 |
Protagenic Stock Against Markets
Protagenic Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Protagenic Therapeutics stock to make a market-neutral strategy. Peer analysis of Protagenic Therapeutics could also be used in its relative valuation, which is a method of valuing Protagenic Therapeutics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Protagenic Therapeutics Corporate Management
| Robert Stein | Chief Director | Profile | |
| CFA MD | CFO Sec | Profile | |
| Garo Armen | CoFounder Chairman | Profile | |
| David Lovejoy | Scientific Officer | Profile | |
| Andrew Slee | Chief Officer | Profile |
Additional Tools for Protagenic Stock Analysis
When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.